Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · Healing & Recovery

BPC-157 vs LL-37

BPC-157 and LL-37 sit in the same broad healing category but target different problems. BPC-157 drives structural repair. LL-37 is a cathelicidin-derived antimicrobial peptide that adds an antimicrobial and immune-modulatory layer.

Bangkok research desk ·

Side-by-side

BPC-157 LL-37
MechanismVEGF upregulation, NO modulation, tissue repair.Broad-spectrum antimicrobial; immune modulation via formyl peptide receptor signalling.
Half-life~4 hours.Short in circulation; active tissue-level effects.
Dose250-500 mcg/day SC.100-500 mcg/day SC (research-dependent).
Cycle4-6 weeks.Research-dependent; shorter protocols common.
Research contextDense preclinical base in tendon, ligament, and gut-mucosal repair1.Antimicrobial, wound-healing, and immune-modulation research2. Caution in autoimmune contexts.
Cost tierLow.Mid.

BPC-157 and LL-37 are both healing-category peptides, but a researcher asking "which should I use" is usually working on two different questions. BPC-157 answers a tissue-repair question: how fast can this ligament, tendon, or GI mucosa recover. LL-37 answers an antimicrobial-plus-immune-modulation question: how do I study host defence peptides and their effect on wound resolution.

LL-37 is a 37-amino-acid cathelicidin fragment with documented antimicrobial activity against a broad spectrum of bacteria, viruses, and fungi, plus signalling roles in wound healing and inflammation2. Its activity depends on local concentration at the wound site and on interaction with host immune receptors. Because it modulates inflammatory signalling in both directions depending on context, research protocols should account for autoimmune contraindications.

BPC-157 has the denser research base for purely structural repair endpoints1. If a researcher is running a tendon-healing study, BPC-157 is the mechanistically relevant compound. If the study targets wound infection, chronic non-healing ulcer, or the interface between host defence and repair, LL-37 is the more specific tool.

Stacking is uncommon in the literature. The two peptides occupy adjacent niches rather than overlapping pathways. For BPC-157 mechanism, see the BPC-157 mechanism deep-dive. For broader healing-stack reasoning, the healing peptide stacking guide covers the trade-offs.

Frequently asked

Does LL-37 have human clinical data?
Human clinical data on LL-37 as a therapeutic is limited; most of the evidence base is preclinical. The endogenous peptide is well-characterised as a component of innate immunity2, but synthetic LL-37 remains a research tool.
Can they be combined?
Combination is uncommon in the literature. If both tissue-repair and antimicrobial questions are relevant to the same protocol, researchers have occasionally used both, but rationale should be specific to the injury or pathogen model.
Why is LL-37 contraindicated in autoimmune conditions?
LL-37 modulates inflammatory signalling and has been implicated in lupus and psoriasis pathology through interaction with nucleic acids and TLRs. Autoimmune context warrants specific caution.
Research desk
Ordering both BPC-157 and LL-37 for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011. PMID: 21030672
  2. Vandamme D, et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012. PMID: 23246832

All references verified against PubMed via NCBI E-utilities.